In order to determine community pharmacists' compliance with FDA PPI regulations, five trained shoppers were sent with estrogen prescriptions to 45 pharmacies in a large Midwestern city. Only 42 percent of the prescriptions dispensed were accompanied by a PPI. Fifty-six percent of the prescriptions were dispensed without safety caps.
In all cases where a correct PPI was received, a follow-up phone call was made to a pharmacist at the pharmacy to determine the accuracy of the response to a question about information in the PPI. Only 39 percent of the pharmacists were able to correctly answer the phone-in question.
MorrisL.A., MyerA., GibbsP., LaoC.Estrogen PPIs — an FDA study. Am Pharm1980; NS20: 318–22.
2.
CampbellR.K., GrisafeJ.A.A study of prescription prices and professional services. J Am Pharm Assoc1977; NS17: 164–7.
3.
JacksonR.A., SmithM.C., MikealR.L.The quality of pharmaceutical services: structure, process and state board requirements. Drugs in Health Care1975; 2: 39–48.
4.
JangR., KnappD.A., KnappD.E.An evaluation of the quality of drug-related services in neighborhood pharmacies. Drugs in Health Care1975; 2: 21–38.
5.
NelsonA.A., HutchinsonR.A., MahoneyD., RingstromJ.Evaluation of the utilization of medication profiles. Drug Intell Clin Pharm1976; 10: 274–81.
6.
CampbellR.K., GrisafeJ.A.Compliance with the Washington state patient information regulation. J Am Pharm Assoc1975; NS15: 494–5, 528.
7.
KnappD.A., WolfH.H., KnappD.E.The pharmacist as a drug advisor. J Am Pharm Assoc1969; NS9: 502–3.
8.
Food and Drug Administration.Requirements for patient labeling for progestational drug products. Federal Register (13 Oct) 1978; 43: 47178–81.
